In Q1 2026, Foresite Capital held 7 positions worth $221.0M. They initiated 1 new position and exited 8. Their largest holding was PHVS ($135.0M). Portfolio value grew +7.8% versus the prior quarter.
Frequently asked questions
What stocks did Foresite Capital own in Q1 2026?
Foresite Capital held 7 biotech stocks in their 13F portfolio in Q1 2026. Their top positions include PHVS, CYTK, EIKN, RLAY, XENE. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Foresite Capital's portfolio worth in Q1 2026?
Foresite Capital's tracked biotech portfolio was worth $221.0M across 7 positions, with total assets under management of approximately $4B. Portfolio values are based on 13F filings with the SEC.
What did Foresite Capital buy in Q1 2026?
Foresite Capital initiated 1 new position in Q1 2026, including EIKN. They also increased 1 existing positions.
What did Foresite Capital sell in Q1 2026?
Foresite Capital fully exited 8 positions in Q1 2026, including ACRS, NTRA, KURA, SNDX, LYEL and 3 more. They also trimmed 1 existing positions.
Is Foresite Capital a biotech fund?
Data science-driven healthcare crossover fund investing from late-stage private through public equity. Uses proprietary data analytics and clinical expertise to identify asymmetric risk/reward opportunities across biotech and life sciences.
Want AI analysis, insider signals, and catalyst overlays for Foresite Capital?
View latest Foresite Capitalportfolio →